CAI
Caris Life Sciences, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Caris Life Sciences, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
SentenceFor example, the February 2024 cybersecurity attack on Change Healthcare, who we used to process certain insurance claims, resulted in a delay in our ability to submit claims for payment and could require us to issue notifications to impacted individuals and various regulators if Change Healthcare determines that any PHI of our patients was impacted.
CAI 10-Kaccession 0002019410-26-000016
SentenceBoth of our Phoenix laboratories hold CAP accreditations upon which our CLIA Certificate of Accreditation are based.
CAI 10-Kaccession 0002019410-26-000016
SentenceTo further broaden the applicability and usefulness of our multi-modal datasets for biopharma companies, we have entered into agreements with clinical data partners, such as ConcertAI, Flatiron and COTA, to enable the creation of matched clinico-genomic datasets that can be licensed to biopharma companies for their use in drug discovery.
CAI 10-Kaccession 0002019410-26-000016
SentenceTo further broaden the applicability and usefulness of our multi-modal datasets for biopharma companies, we have entered into agreements with clinical data partners, such as ConcertAI, Flatiron and COTA, to enable the creation of matched clinico-genomic datasets that can be licensed to biopharma companies for their use in drug discovery.
CAI 10-Kaccession 0002019410-26-000016
SentenceThe test was developed using tumor specimens and clinical data from the TAILORx (ECOG) and B-42 (NRG) randomized clinical trials.
CAI 10-Kaccession 0002019410-26-000016
SentenceTo further broaden the applicability and usefulness of our multi-modal datasets for biopharma companies, we have entered into agreements with clinical data partners, such as ConcertAI, Flatiron and COTA, to enable the creation of matched clinico-genomic datasets that can be licensed to biopharma companies for their use in drug discovery.
CAI 10-Kaccession 0002019410-26-000016
SentenceThe test was developed using tumor specimens and clinical data from the TAILORx (ECOG) and B-42 (NRG) randomized clinical trials.
CAI 10-Kaccession 0002019410-26-000016
SentenceIn July 2024, we entered into a master supply agreement with Roche Diagnostics Corporation ("Roche"), for Roche to provide sequencing probes and other testing supplies and equipment for clinical and research uses in our laboratory operations (the "Roche Agreement").
CAI 10-Kaccession 0002019410-26-000016
SentenceThrough an exclusive license arrangement with Washington University in St. Louis ("WashU") that we entered into in October 2024, we are developing Caris ChromoSeq, an assay that detects and analyzes hematological cancers using WGS and WTS.
CAI 10-Kaccession 0002019410-26-000016
SentenceOur molecular profiling solutions and the data generated by our multi-omic technology platform also provide value to our biopharma partners, such as Moderna, AbbVie, Xencor, Merck KGaA and Genentech, through partnerships that aim to increase the probability of technical and regulatory success of their therapeutic pipelines.
SentenceOur molecular profiling solutions and the data generated by our multi-omic technology platform also provide value to our biopharma partners, such as Moderna, AbbVie, Xencor, Merck KGaA and Genentech, through partnerships that aim to increase the probability of technical and regulatory success of their therapeutic pipelines.
SentenceOur molecular profiling solutions and the data generated by our multi-omic technology platform also provide value to our biopharma partners, such as Moderna, AbbVie, Xencor, Merck KGaA and Genentech, through partnerships that aim to increase the probability of technical and regulatory success of their therapeutic pipelines.
SentenceWe have entered into a collaboration agreement with Everlywell to expand access to Caris Detect.
CAI 10-Kaccession 0002019410-26-000016
SentenceOur molecular profiling solutions and the data generated by our multi-omic technology platform also provide value to our biopharma partners, such as Moderna, AbbVie, Xencor, Merck KGaA and Genentech, through partnerships that aim to increase the probability of technical and regulatory success of their therapeutic pipelines.
CAI 10-Kaccession 0002019410-26-000016
SentenceWe have obtained Medicare coverage under the NGS NCD for MI Cancer Seek for CPT code 0211U.
CAI 10-Kaccession 0002019410-26-000016
SentenceOur molecular profiling solutions and the data generated by our multi-omic technology platform also provide value to our biopharma partners, such as Moderna, AbbVie, Xencor, Merck KGaA and Genentech, through partnerships that aim to increase the probability of technical and regulatory success of their therapeutic pipelines.
CAI 10-Kaccession 0002019410-26-000016
Caris Life Sciences has 11 disclosed suppliers and 7 disclosed customers in SEC filings.
Caris Life Sciences, Inc.
34.33
Linked news
Expected move
Inputsstraddle ±16.7%
spot 34.33exp Nov 20ATM strike 35ATM straddle 6.75IV 102%